H.C. Wainwright resumed coverage on Aethlon Medical with a new price target
$AEMD
Medical/Dental Instruments
Health Care
H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2025 | $1.50 | Neutral | H.C. Wainwright |
| 6/25/2021 | $5.00 → $9.00 | Buy | HC Wainwright & Co. |
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
424B5 - AETHLON MEDICAL INC (0000882291) (Filer)
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50
HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology. According to recent reports from the World Health Organization ("WHO") and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a
Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t
Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments. Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr
SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)